Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases

N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases

US Patent 8404896 · Granted Mar 26, 2013

Estimated economic value: $66,062,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Pyrrolidinone derivatives as formyl peptide 2 receptor agonists2025
Fused pentacyclic imidazole derivatives2024
Fused pentacyclic imidazole derivatives as modulators of TNF activity2023
Quinazolines as potassium ion channel inhibitors2021
Fused pentacyclic imidazole derivatives as modulators of TNF activity2021
Fused pentacyclic imidazole derivatives as modulators of TNF activity2021
Fused pentacyclic imidazole derivatives2021
Compounds useful as immunomodulators2020
Quinazolines as potassium ion channel inhibitors2020
Hepatitis C virus inhibitors2020
6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists2020
2,4-dihydroxy-nicotinamides as APJ agonists2019